Front Row Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Front Row Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$699	–	516
2024 Q4	$699	Hold	20	–	–	﹤0.01%	467
2024 Q3	$801	Hold	20	–	–	﹤0.01%	466
2024 Q2	$953	Hold	20	–	–	﹤0.01%	893
2024 Q1	$867	Hold	20	–	–	﹤0.01%	886
2023 Q4	$1.01K	Hold	20	–	–	﹤0.01%	435
2023 Q3	$907	Hold	20	–	–	﹤0.01%	870
2023 Q2	$1K	Hold	20	–	–	﹤0.01%	857
2023 Q1	$1K	Buy	+20	New	+$751	﹤0.01%	875

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Front Row Advisors's IONS Position: Q1 2025 in Review

Front Row Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2025, closing a stake of 20 shares — an estimated $699 sold.

Front Row Advisors first reported a position in IONS in Q1 2023 and held it in 8 quarters. The position peaked at $1.01K in Q4 2023. 343 funds tracked by Wall St. Rank hold IONS as of Q1 2025.

Front Row Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Front Row Advisors sold 20 Ionis Pharmaceuticals shares in Q1 2025, an estimated $699.
Front Row Advisors first reported a position in Ionis Pharmaceuticals in Q1 2023 and held it in 8 quarters.
Front Row Advisors's Ionis Pharmaceuticals position peaked at $1.01K in Q4 2023.
343 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2025.

Based on Front Row Advisors's 13F filing for Q1 2025, filed 15 May 2025.